Back to PT-141Peptide-specific calculator
PT-141 dosage calculator
Calculate PT-141 concentration, syringe units, doses per vial, and vial longevity from the protocol data.
Target dose per injection: 0.5 mgFrequency: as neededStatic chart: 5 mg vial
The chart is educational math only. Use clinician-directed instructions for real treatment decisions.
Prefilled calculator
Reconstitution & dosage calculator
Use the prefilled calculator for the current protocol, then compare common bacteriostatic-water volumes in the static chart below.
Static chart: 5 mg vial
Reconstitution chart
Common bacteriostatic-water options for the starting protocol.
| Bacteriostatic water (ml) | Concentration | Units to draw per dose | ml per dose | Doses per vial | Days a vial lasts |
|---|---|---|---|---|---|
| 1 ml | 5 mg/ml | 10 | 0.1 ml | 10 | 70 |
| 2 ml | 2.5 mg/ml | 20 | 0.2 ml | 10 | 70 |
| 3 ml | 1.667 mg/ml | 30 | 0.3 ml | 10 | 70 |
Protocol table
Advanced
1.75 mg
as needed
Routesubcut
Injection timing1 weeks on / 0 weeks off
Approved dose for HSDD.
Beginner
0.5 mg
as needed
Routesubcut
Injection timing1 weeks on / 0 weeks off
Standard
1 mg
as needed (≤45 min before activity)
Routesubcut
Injection timing1 weeks on / 0 weeks off
Safety summary
Contraindications
- Uncontrolled hypertension — the BP bump on top of poorly-controlled baseline is the safety concern that bounded the label
- Known cardiovascular disease, recent MI or stroke
- Pregnancy
- Concurrent indinavir or other narrow-therapeutic-window oral drugs — bremelanotide slows GI absorption transiently
Side effects
- moderateNausea is the most common side effect — roughly 40% of trial participants at the 1.75 mg approved dose. Drops sharply at 1 mg.
- moderateFlushing and a transient blood pressure rise (about 6 mmHg systolic on average) for 4–6 hours.
- mildHeadache, usually mild and self-limited.
- moderateFocal hyperpigmentation with frequent use — gums, face, breasts. The MC1R cross-activation is the mechanism.
PT-141
Melanocortin-receptor agonist that works on desire in the brain, not blood flow in the pelvis. FDA-approved as Vyleesi for premenopausal HSDD.